Lifeboat Foundation

Cells that become senescent irrevocably stop dividing under stress, spewing out a mix of inflammatory proteins that lead to chronic inflammation as more and more of the cells accumulate over time. Publishing in the September 24 edition of Cell Reports, researchers at the Buck Institute identified 44 specific senescence-associated proteins that are involved in blood clotting, marking the first time that cellular senescence has been associated with age-related blood clots.

“The incidence of venous thrombosis, which includes deep vein thrombosis and pulmonary embolism is extremely low until the age of 45, when it begins to rise rapidly. Over time it becomes a major risk factor for death. By 80, the condition affects five to six people per thousand individuals,” said Judith Campisi, PhD, Buck professor and senior co-author of the study. “Blood clots are also a serious side effect of chemotherapy, which sets off a cascade of senescence in those undergoing treatment. That’s why blood thinners, which carry their own risks, are often included in treatment protocols.”

Scientists in the Campisi lab and other labs around the world are working to develop senolytics, drugs which would clear senescent cells from the body, potentially providing treatment options for many age-related diseases that are either caused or linked to senescence. They include Alzheimer’s and Parkinson’s diseases, cardiovascular disease, osteoarthritis, macular degeneration, age-related cancers and sarcopenia, among others.

In this issue of Cell, Baar et al. show how FOXO4 protects senescent cell viability by keeping p53 sequestered in nuclear bodies, preventing it from inducing apoptosis. Disrupting this interaction with an all-D amino acid peptide (FOXO4-DRI) restores p53’s apoptotic role and ameliorates the consequences of senescence-associated loss of tissue homeostasis.

Most EV attention focuses on cars and SUVs, but medium and large electrified trucks for local and regional deliveries are coming to market, too, including from Volvo.

A SCIENTIST tabled an alternative theory on black holes during a documentary, building on Albert Einstein’s general relativity theory to claim it is possible to escape, “like a science fiction story”.

It’s hard living in a relativistic Universe, where even the nearest stars are so far away and the speed of light is absolute. It is little wonder then why science fiction franchises routinely employ FTL (Faster-than-Light) as a plot device.

Push a button, press a petal, and that fancy drive system – whose workings no one can explain – will send us to another location in space-time.

However, in recent years, the scientific community has become understandably excited and skeptical about claims that a particular concept – the Alcubierre Warp Drive – might actually be feasible.

Thanks to solar-powered propulsion and household (meaning no generators are required to run the lights, air conditioning, etc.), and with electric propulsion when needed, the 56-foot catamaran has unlimited range, no noise or fumes, minimal vibration and is virtually maintenance-free. It’s smooth and serene cruising at its best where both the environment and owner’s enjoyment come first. And operation costs are kept to a minimum, too.

Researchers from North Carolina State University have demonstrated that exosomes harvested from human skin cells can repair sun-damaged skin cells in mice. The therapy also appears to be more effective than retinol and stem cell treatment, and best of all, delivery of the therapy is needle-free.

What are exosomes?

Exosomes are essentially membrane-wrapped packages that contain proteins and other molecules, are produced and released by cells, and deliver messages to other cells. When nearby cells intercept these packages, they change their behavior based on the information contained in these packages. You might think of exosomes being almost like messages in bottles traveling in the bloodstream between cells.

We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.

Dr. Kelsey Moody gave a detailed presentation on macular degeneration, discussing its origins in the lysosomes and how it progresses along with how his company, Ichor Therapeutics, is developing an exogenous enzyme treatment that may cure this crippling disease.

OpenAI have taught their AI agents to play hide and seek to show how they can develop their own complex and intelligent behaviours 🤖.